Means Investment CO. Inc. Decreases Position in Jazz Pharmaceuticals PLC (JAZZ)

Means Investment CO. Inc. cut its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 8.1% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,540 shares of the specialty pharmaceutical company’s stock after selling 225 shares during the quarter. Means Investment CO. Inc.’s holdings in Jazz Pharmaceuticals were worth $363,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. JPMorgan Chase & Co. grew its stake in Jazz Pharmaceuticals by 3.0% in the third quarter. JPMorgan Chase & Co. now owns 1,912,173 shares of the specialty pharmaceutical company’s stock valued at $321,494,000 after purchasing an additional 56,291 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Jazz Pharmaceuticals by 14.0% in the third quarter. Bank of New York Mellon Corp now owns 1,690,385 shares of the specialty pharmaceutical company’s stock valued at $284,205,000 after purchasing an additional 207,954 shares in the last quarter. Martingale Asset Management L P grew its stake in Jazz Pharmaceuticals by 10,786.8% in the third quarter. Martingale Asset Management L P now owns 174,516 shares of the specialty pharmaceutical company’s stock valued at $29,342,000 after purchasing an additional 172,913 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Jazz Pharmaceuticals by 4.1% in the third quarter. Dimensional Fund Advisors LP now owns 302,539 shares of the specialty pharmaceutical company’s stock valued at $50,861,000 after purchasing an additional 11,988 shares in the last quarter. Finally, United Services Automobile Association grew its stake in Jazz Pharmaceuticals by 53.4% in the third quarter. United Services Automobile Association now owns 18,537 shares of the specialty pharmaceutical company’s stock valued at $3,117,000 after purchasing an additional 6,455 shares in the last quarter. Institutional investors and hedge funds own 93.41% of the company’s stock.

A number of research firms have recently issued reports on JAZZ. Cantor Fitzgerald set a $201.00 price objective on Jazz Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, January 4th. BidaskClub raised Jazz Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, December 18th. Oppenheimer set a $180.00 price objective on Jazz Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, December 23rd. TheStreet cut Jazz Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Tuesday, February 19th. Finally, Zacks Investment Research raised Jazz Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 8th. Five analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. Jazz Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $182.71.

NASDAQ:JAZZ traded down $2.26 during mid-day trading on Tuesday, hitting $136.13. 14,965 shares of the stock were exchanged, compared to its average volume of 612,959. The stock has a market cap of $7.90 billion, a P/E ratio of 11.23, a PEG ratio of 0.91 and a beta of 1.23. The company has a current ratio of 3.57, a quick ratio of 3.42 and a debt-to-equity ratio of 0.57. Jazz Pharmaceuticals PLC has a fifty-two week low of $113.52 and a fifty-two week high of $184.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, February 26th. The specialty pharmaceutical company reported $3.27 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.66 by $0.61. The business had revenue of $476.46 million during the quarter, compared to analysts’ expectations of $459.48 million. Jazz Pharmaceuticals had a return on equity of 26.20% and a net margin of 23.64%. The firm’s revenue for the quarter was up 9.2% compared to the same quarter last year. During the same period last year, the firm posted $2.95 EPS. As a group, sell-side analysts forecast that Jazz Pharmaceuticals PLC will post 13.19 EPS for the current year.

In other Jazz Pharmaceuticals news, CFO Matthew P. Young sold 1,916 shares of Jazz Pharmaceuticals stock in a transaction on Wednesday, February 27th. The stock was sold at an average price of $131.46, for a total value of $251,877.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Suzanne Sawochka Hooper sold 6,666 shares of Jazz Pharmaceuticals stock in a transaction on Wednesday, February 27th. The shares were sold at an average price of $140.00, for a total value of $933,240.00. Following the completion of the transaction, the executive vice president now directly owns 40,401 shares of the company’s stock, valued at $5,656,140. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,668 shares of company stock valued at $1,606,567. 3.90% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: This story was published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.com-unik.info/2019/04/16/means-investment-co-inc-decreases-position-in-jazz-pharmaceuticals-plc-jazz.html.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Recommended Story: How Short Selling Works

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit